---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-24-000100"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:48:39.792204+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cartesian reports positive Phase 2b MG data, Q2 net income $13.8M, $130M PIPE

## Summary
- Phase 2b trial of Descartes-08 in MG met primary endpoint: 71% (10/14) of treated patients vs 25% (3/12) placebo had ≥5-point MGC improvement at Month 3 (p=0.018).
- Q2 2024 net income of $13.8M ($0.58/share) vs net loss of $11.4M ($2.23/share) in Q2 2023; revenue included $30M milestone from Sobi.
- Completed $130M PIPE financing in July 2024; cash and equivalents $88.9M at June 30, 2024, expected to fund Phase 3 MG trial and early commercial prep.
- Dosed first SLE patient in Phase 2 trial; IND filing for pediatric basket study expected by year-end 2024; Descartes-15 Phase 1 expected H2 2024.
- Appointed Dr. Kemal Malik to board; End-of-Phase 2 FDA meeting expected by year-end 2024.

## SEC filing metadata
- accession: 0001453687-24-000100
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000100/0001453687-24-000100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000100/rnac-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-24-000100
- JSON: https://secwatch.observer/filing/0001453687-24-000100.json
- Plain text: https://secwatch.observer/filing/0001453687-24-000100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.